Chronic lymphocytic leukaemia
Not recruitingStudy on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments
Study on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments
- Disease:Chronic lymphocytic leukaemia
- Substances:ObinutuzumabVenetoclax
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Obinutuzumab
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting









